 | Up a level |
Lloyd, Katie and Papoutsopoulou, Stamatia 
ORCID: 0000-0001-6665-8508
(2020)
First person - Katie Lloyd and Stamatia Papoutsopoulou.
DISEASE MODELS & MECHANISMS, 13 (11).
Harman, Nicola L ORCID: 0000-0001-6958-6466, Sanz-Moreno, Adrian, Ameen-Ali, Kamar E, Papoutsopoulou, Stamatia ORCID: 0000-0001-6665-8508, Lloyd, Katie, Garcia-Finana, Marta ORCID: 0000-0003-4939-0575, MacLeod, Malcolm and Williamson, Paula R ORCID: 0000-0001-9802-6636
(2019)
MOUSE - Mapping OUtcomes measured in pre-clinical Studies against randomised phase 3/4 Effectiveness trials. Do core outcome sets developed for phase3/4 effectiveness trials translate to pre-clinical research?
In: International Clinical Trials Methodology Conference, 2019-10-7 - 2019-10-9, Brighton.
Lloyd, Katie, Papoutsopoulou, Stamatia ORCID: 0000-0001-6665-8508, Smith, Emily, Stegmaier, Philip, Bergey, Francois, Morris, Lorna, Kittner, Madeleine, England, Hazel, Spiller, Dave, White, Mike HR et al (show 9 more authors)
(2020)
Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease.
DISEASE MODELS & MECHANISMS, 13 (11).
dmm044040-.
Lloyd, Katie ORCID: 0000-0002-2325-8050, Papoutsopoulou, Stamatia, Smith, Emily, Stegmaier, Philip ORCID: 0000-0002-1881-8746, Bergey, Francois, Morris, Lorna, Kittner, Madeleine, England, Hazel ORCID: 0000-0002-8324-614X, Spiller, Dave ORCID: 0000-0003-2502-6787, White, Mike HR ORCID: 0000-0002-3617-3232 et al (show 10 more authors)
(2020)
Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease.
Disease models & mechanisms.